Vicept Acquired By Allergan For $75M Upfront
This article was originally published in The Pink Sheet Daily
Allergan adds to its dermatology portfolio with the acquisition of closely-held Vicept.
You may also be interested in...
The dermatology company is able to offer a continuum of care for patients with the skin condition now that it has received FDA approval for a third product to treat the condition. The latest offering treats the most mild form of the condition.
Plus news on recent financings by bluebird bio, Puma Biotechnology, Atara Biotherapeutics and Aclaris Therapeutics.
Newly launched dermatology start-up Aclaris brings the band back together, as Vicept’s core management and VCs begin a new endeavor in a sometimes-neglected sector.